logo-loader
viewCello Health PLC

Notification of Half Year Results

/**/ h1{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:18.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h2{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Arial","sans-serif";font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Times New Roman","serif";font-weight:bold;}h4{margin-top:12.0pt;margin-right:0cm;margin-bottom:3.0pt;margin-left:0cm;font-size:14.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h6{margin:0cm;margin-bottom:.0001pt;text-align:justify;font-size:10.5pt;font-family:"Times","serif";text-transform:uppercase;font-weight:normal;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .bz{size:595.3pt 841.9pt;margin:53.85pt 72.0pt 36.0pt 36.85pt;}div.bz{}p.cu{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";font-weight: bold; margin-left: 1.0cm; text-autospace: none; vertical-align: baseline}p.cv{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";font-weight: bold; margin-left: 1.0cm; text-align: center; text-autospace: none; vertical-align: baseline}p.cw{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";margin-left: 1.0cm; text-align: center; text-autospace: none; vertical-align: baseline}p.cx{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";margin-left:1.0cm;text-autospace:none;vertical-align: baseline}span.cp{font-size:8.0pt}p.cy{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";margin-left:1.0cm;text-align:justify;text-autospace: none;vertical-align:baseline}p.cz{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";font-weight: bold; text-autospace: none; vertical-align: baseline}p.da{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";font-weight: bold; line-height: 115%; margin-bottom: 8.0pt; margin-left: 1.0cm; margin-right: 0cm; margin-top: 0cm; text-autospace: none; vertical-align: baseline} table.db{width:462.1pt;margin-left:-5.4pt;border-collapse:collapse}tr.cg{height:15.2pt}td.ci{width:220.25pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.2pt}p.dc{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";margin-left:23.0pt}span.ck{color:black}p.dd{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";font-weight: bold; margin-left: 23.0pt}span.ce{line-height:115%}p.de{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif"; font-weight: bold; margin-left: 1.0cm; text-align: justify}p.df{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";margin-top:0cm;margin-right:0cm;margin-bottom:12.0pt; margin-left:1.0cm;text-align:justify;vertical-align:top}p.dg{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";font-weight: bold; line-height: 115%; margin-bottom: 10.0pt} span.cb{font-size:12.0pt;line-height:115%;color:black;border:none} /**/
RNS Number : 9549H
Cello Health PLC
06 August 2019
 

For immediate release                                                                                       6 August 2019

 

 

 

Cello Health plc

("Cello" or the "Group")

 

Notification of Half Year Results

 

 

Cello Health plc (AIM: CLL), the global healthcare-focused advisory group, will announce its interim results for the six months ended 30 June 2019 on Wednesday 18 September 2019.

 

A meeting for analysts will be held at 9.30am on the morning of the results announcement at the offices of Buchanan, 107 Cheapside, London EC2V 6DN. For further details please contact Buchanan on 020 7466 5000 or email [email protected].

 

 

Enquiries:

Cello Health plc

020 7812 8460

Mark Scott, Chief Executive


Mark Bentley, Group Finance Director




Cenkos Securities plc

020 7397 8900

Mark Connelly


Harry Hargreaves




Buchanan

020 7466 5000

Mark Court


Jamie Hooper


Sophie Wills


 

About Cello Health plc

 

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORPAMATMBTMBAL

Quick facts: Cello Health PLC

Price: 138

Market: AIM
Market Cap: £146.6 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Cello Health reports good growth in profits and strong cash flow

Cello Health PLC's (LON:CLL) Mark Scott tells Proactive London they've seen good growth in profits and strong cash flow for the first half of the year said that he's confident about the rest of the year too. The group delivered net revenue of £54.5mln for the first six months of the year,...

on 18/9/19

RNS

Pre-Close Trading Statement

2 days, 11 hours ago

Total Voting Rights

on 3/12/19

Holding(s) in Company

on 22/11/19

Holding(s) in Company

on 14/11/19

Total Voting Rights

on 13/11/19

Total Voting Rights

on 7/10/19

Disposal

on 2/10/19